109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
金银花来源的类外泌体纳米囊泡通过调节肠道菌群预防急性肝衰竭
Authors Li P , Tang Y, Chen Y, Fan W, Yao J, Yu K, Shan Y , Wang J, Ye XM , Zou H, Mou X
Received 7 March 2025
Accepted for publication 2 October 2025
Published 25 October 2025 Volume 2025:20 Pages 12975—12992
DOI https://doi.org/10.2147/IJN.S526819
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Jie Huang
Ping Li,1– 3 Yan Tang,1,3,4 Yixun Chen,1,3,4 Weijiao Fan,1,3 Jiayu Yao,1,3 Kexin Yu,1,3 Yiyi Shan,1,3 Jie Wang,5 Xiang Ming Ye,1 Hai Zou,6 Xiaozhou Mou1,3
1Center for Rehabilitation Medicine, Rehabilitation and Sports Medicine Research Institute of Zhejiang Province, Department of Rehabilitation Medicine, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, People’s Republic of China; 2College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, People’s Republic of China; 3Clinical Research Institute, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, People’s Republic of China; 4College of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, People’s Republic of China; 5EVital Bio (Hangzhou) Co., Ltd, Hangzhou, People’s Republic of China; 6Department of Critical Care, Shanghai Cancer Center, Fudan University, Shanghai, People’s Republic of China
Correspondence: Hai Zou, Email zouhai@fudan.edu.cn Xiaozhou Mou, Email mouxz@zju.edu.cn
Purpose: Acute liver failure (ALF) is a rare but life-threatening condition caused by drug toxicity, viral infections, or autoimmune disorders. Current treatments rely heavily on liver transplantation, which is costly and high-risk. As most therapies target single mechanisms, developing safe, cost-effective multi-target drugs is urgently needed.
Methods: In this study, we isolated exosome-like nanovesicles from dried honeysuckle (HNVs) and evaluated their therapeutic potential in a lipopolysaccharide/D-galactosamine (LPS/GalN)-induced ALF mouse model. We first characterized HNVs using cryo-electron microscopy (Cryo-EM), transmission electron microscopy (TEM), and dynamic light scattering (DLS), and confirmed their stability in gastrointestinal simulation fluid in vivo. Subsequently, we validated the biological safety and in vivo distribution of HNVs in mice. Afterwards, we constructed an ALF model and tested the therapeutic efficacy of HNVs on this model. Through RNA sequencing, 16S rRNA analysis, and complementary techniques such as Western blot and quantitative real-time PCR, we elucidated the underlying mechanisms of HNVs in mitigating ALF.
Results: Our results showed that HNVs significantly ameliorated the pathological symptoms associated with ALF mice. Specifically, HNVs induced a significant 1.89-fold decrease in serum ALT levels and a 1.95-fold decrease in AST levels. HNVs also ameliorated the hepatocellular necrosis and inflammatory cell infiltration caused by LPS/GalN. In addition, our findings suggest that the mechanism by which HNVs ameliorate ALF is: (1) they directly target the liver by traversing the compromised intestinal barrier, suppressing hepatic immune-inflammatory responses, and ameliorating ALF; (2) they restore intestinal barrier integrity by modulating the gut microbiota, thus reducing the translocation of gut-derived LPS to the liver and preventing further hepatic injury.
Conclusion: In summary, we developed a novel natural nanomedicine with dual-targeting capabilities and demonstrated its efficacy against ALF, offering a promising therapeutic alternative for this severe condition.
Keywords: acute liver failure, Honeysuckle-derived exosome-like nanovesicles, gut microbiota, immune-inflammatory responses
1Center for Rehabilitation Medicine, Rehabilitation and Sports Medicine Research Institute of Zhejiang Province, Department of Rehabilitation Medicine, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, People’s Republic of China; 2College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, People’s Republic of China; 3Clinical Research Institute, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, People’s Republic of China; 4College of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, People’s Republic of China; 5EVital Bio (Hangzhou) Co., Ltd, Hangzhou, People’s Republic of China; 6Department of Critical Care, Shanghai Cancer Center, Fudan University, Shanghai, People’s Republic of China
Correspondence: Hai Zou, Email zouhai@fudan.edu.cn Xiaozhou Mou, Email mouxz@zju.edu.cn
Purpose: Acute liver failure (ALF) is a rare but life-threatening condition caused by drug toxicity, viral infections, or autoimmune disorders. Current treatments rely heavily on liver transplantation, which is costly and high-risk. As most therapies target single mechanisms, developing safe, cost-effective multi-target drugs is urgently needed.
Methods: In this study, we isolated exosome-like nanovesicles from dried honeysuckle (HNVs) and evaluated their therapeutic potential in a lipopolysaccharide/D-galactosamine (LPS/GalN)-induced ALF mouse model. We first characterized HNVs using cryo-electron microscopy (Cryo-EM), transmission electron microscopy (TEM), and dynamic light scattering (DLS), and confirmed their stability in gastrointestinal simulation fluid in vivo. Subsequently, we validated the biological safety and in vivo distribution of HNVs in mice. Afterwards, we constructed an ALF model and tested the therapeutic efficacy of HNVs on this model. Through RNA sequencing, 16S rRNA analysis, and complementary techniques such as Western blot and quantitative real-time PCR, we elucidated the underlying mechanisms of HNVs in mitigating ALF.
Results: Our results showed that HNVs significantly ameliorated the pathological symptoms associated with ALF mice. Specifically, HNVs induced a significant 1.89-fold decrease in serum ALT levels and a 1.95-fold decrease in AST levels. HNVs also ameliorated the hepatocellular necrosis and inflammatory cell infiltration caused by LPS/GalN. In addition, our findings suggest that the mechanism by which HNVs ameliorate ALF is: (1) they directly target the liver by traversing the compromised intestinal barrier, suppressing hepatic immune-inflammatory responses, and ameliorating ALF; (2) they restore intestinal barrier integrity by modulating the gut microbiota, thus reducing the translocation of gut-derived LPS to the liver and preventing further hepatic injury.
Conclusion: In summary, we developed a novel natural nanomedicine with dual-targeting capabilities and demonstrated its efficacy against ALF, offering a promising therapeutic alternative for this severe condition.
Keywords: acute liver failure, Honeysuckle-derived exosome-like nanovesicles, gut microbiota, immune-inflammatory responses